Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CuteAMP CUTibacterium acnes Engineered for Antimicrobial peptide Momentary Production

Coordinator
Universidad Pompeu Fabra, Spain
Runs
1 February 2026 to 31 January 2028
Status
Running
EU funding
€194k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101203174

What the project is doing

In the project's own words, from its summary on CORDIS.

Our skin is colonized by a myriad of bacteria, fungi and viruses that are collectively called the skin microbiota. The most common and consequential bacterial skin pathogen in humans is Staphylococcus aureus. It is an invasive pathogen responsible for varied ailments that commonly evolves resistance to antibiotics. Antimicrobial peptides (AMPs) have drawn interest from the scientific community because they are less prone to resistance development.

However, they typically require complex formulations to enhance their half-life due to low stability, which decrease their efficiencies when topically applied. I propose to genetically engineer Cutibacterium acnes, one of the most prevalent and abundant commensal microbes of the human skin, to produce AMPs for the treatment of S. aureus-associated skin infections. For this, I will develop a novel expression platform based on a synthetic linear plasmid with features of bacterial telomeres that will be progressively degraded after a limited number of replication cycles.

I will also screen AMPs for their potency and specificity against S. aureus and the best candidates will be encoded on the linear plasmid. The use of the linear plasmid as a platform of AMPs production will (i) ensure that the delivery of the AMP is limited in time to prevent the development of antibiotic resistance, and (ii) provide a stringent biocontainment of the modified bacteria, as engineered cells eventually revert to their wild-type genotype upon programmed plasmid loss.

This project merges my expertise in synthetic biology and biochemistry with that of the host in engineering the skin microbiota. The linear plasmid with pre-programmed degradation will be a foundational tool for future engineering of commensal bacteria as live therapeutics. It will also represent a paradigm shift in biocontainment for genetically engineered organisms, that will hopefully bring the use of engineered skin bacteria for microbiome-based therapy a step closer to reality

Topics

Who is involved

OrganisationCityCountryRole
Universidad Pompeu FabraBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI